Extended Data Fig. 3: LRRC15 expression is restricted to tumour-associated fibroblasts.
From: LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity
a. Quantification of frequency of LRRC15+ cells in subcutaneous KPR tumours 17 days post implantation in PDPN+ fibroblasts, CD31+ blood endothelial cells (BEC), PDPN–CD31– stromal cells, CD45+ immune cells, and CD24+ tumour cells (n = 10 mice). b. Representative LRRC15 in situ hybridization images of select healthy murine tissues and subcutaneous KPR tumour tissue 17 days post implantation. c. Bulk RNAseq data of 17 normal mouse tissues showing Lrrc15 and Gapdh (control) expression. Number of samples per tissue are in the source data. d-f. Fap, Acta2, and Lrrc15 gene expression from d. scRNAseq analysis of fibroblasts, immune cells, endothelial cells, and pericytes from KPR tumours 21 days post implantation in Dptwt/wtTgfbr2fl/fl mice. e. scRNAseq of Pdgfrα+ steady state fibroblasts across murine tissues. f. scRNAseq of fibroblasts and pericytes from murine naive skin-draining lymph nodes along with Ccl19 expression. Data in a are pooled from three independent experiments. Data in b are representative of one independent experiment. Data in a are mean +/− s.d. In data in c, whiskers represent the minimum and maximum, the box represents IQR, and the center line represents the median. Statistics in a were calculated using an ordinary one-way ANOVA test.